What is Celmatix?
Celmatix Inc. is a US-based biotechnology company dedicated to pioneering advancements in women's health. The company focuses on developing innovative therapeutics that capitalize on a deeper understanding of female biology. Its product pipeline includes a first-in-class oral FSH receptor agonist designed to enhance fertility care, a novel JNK inhibitor targeting endometriosis, and early-stage antibodies aimed at controlling ovarian folliculogenesis. Celmatix is committed to addressing significant health challenges such as endometriosis and Polycystic Ovary Syndrome (PCOS) through rigorous research and development, aiming to redefine standards of care in this underserved sector.
How much funding has Celmatix raised?
Celmatix has raised a total of $54.1M across 9 funding rounds:
Private Equity
$806K
Series A
$1.5M
Private Equity
$4M
Private Equity
$5.5M
Private Equity
$3.8M
Private Equity
$4.8M
Private Equity
$21M
Other Financing Round
$12.5M
Private Equity (2011): $806K, investors not publicly disclosed
Series A (2012): $1.5M supported by Topspin Partners
Private Equity (2013): $4M, investors not publicly disclosed
Private Equity (2014): $5.5M, investors not publicly disclosed
Private Equity (2015): $3.8M, investors not publicly disclosed
Private Equity (2016): $4.8M, investors not publicly disclosed
Private Equity (2016): $21M supported by Topspin Partners
Other Financing Round (2017): $12.5M featuring Topspin Partners
Key Investors in Celmatix
Topspin Partners
Topspin Partners is a private equity firm focused on growing branded consumer products and services companies. They provide strategic guidance and capital to enhance operational improvements and facilitate company expansion.
What's next for Celmatix?
The substantial enterprise-level funding and major strategic investment received by Celmatix indicate a strong market validation and provide the necessary resources for the company to accelerate its development pipeline. This capital infusion is expected to fuel the progression of its novel therapeutics through clinical trials and towards commercialization. Celmatix's focus on addressing critical unmet needs in women's health positions it for significant growth and impact, potentially transforming patient outcomes for conditions like endometriosis and PCOS. The company's trajectory suggests a move towards scaling operations and expanding its therapeutic offerings.
See full Celmatix company page
